First FDA-Approved Recombinant von Willebrand Factor, Vonvendi, Now Available for von Willebrand Disease

The following is excerpted from a press release from Baxalta, now a part of Shire. Read the press release in it’s entirety here.
Shire has announced that Vonvendi [von Willebrand factor (Recombinant)], indicated for the on-demand treatment and control of bleeding episodes in adults (age 18 and older) diagnosed with von Willebrand disease, is now available from Shire’s Hematology Support Center (HSC) through a patient service model.
Patients interested in Vonvendi  should speak with their healthcare provider to determine if Vonvendi  is right for them.  Starting on Vonvendi will require a healthcare provider to enroll the patient in an Activation Program.  To learn more about the drug, visit http://www.vonvendi.com.